Cornucopian Capital
VC Fund
Montclair, United States
Cornucopian Capital is a seeding innovation at the nexus of food and health.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Cornucopian Capital invests in
Stages Cornucopian Capital invests in
Countries Cornucopian Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aryeh Ganz
|
|||
4 more contacts available
Investment Focus
Industry
- Health Care 3 (38%)
- Biotechnology 3 (38%)
- Fitness 1 (13%)
- Wellness 1 (13%)
- Analytics 1 (13%)
Stage
- Seed 3 (38%)
- Series A 3 (38%)
- Series B 2 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Aryeh Ganz
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Handspring Health
|
Handspring is redesigning the family mental healthcare experience from the ground up. Our omnichannel care delivery model tightly integrates different modalities of care, including in-person, digital and devices. Through the use of technology, health plan partnerships, and highly trained clinicians. Handspring Health aims to make quality mentalhealthcare more accessible to all families. | $19M / Series B / Jul 07, 2026 | |
Ilant Health
|
Ilant Health provides treatment for obesity and weight management. | $15M / Series A / Apr 09, 2026 | |
Excelsior Sciences
|
Excelsior Sciences develops a chemistry and AI platform for discovering and manufacturing small-molecule compounds. It uses a proprietary “smart bloccs” system, which consists of modular, machine-ready chemical building blocks, to convert small-molecule innovation into an iterative, automation-friendly workflow. Through this platform, Excelsiorenables closed-loop cycles of AI-guided synthesis, testing, and optimisation that link early-stage discovery to scalable manufacturing. The company supports projects across pharmaceuticals, materials science, and other sectors that rely on small molecules. Excelsior also maintains an internal pipeline of therapeutic candidates while working with partners to deploy its chemistry platform broadly. | $70M / Series A / Dec 03, 2025 | |
|
Handspring Health
|
Handspring is redesigning the family mental healthcare experience from the ground up. Our omnichannel care delivery model tightly integrates different modalities of care, including in-person, digital and devices. Through the use of technology, health plan partnerships, and highly trained clinicians. Handspring Health aims to make quality mentalhealthcare more accessible to all families. | $12M / Series A / Jun 26, 2025 | |
Archon Biosciences
|
Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management. | $20M / Seed / Oct 30, 2024 | |
|
Ilant Health
|
Ilant Health provides treatment for obesity and weight management. | $2.5M / Seed / Apr 17, 2024 | |
InsideTracker
|
InsideTracker is a personalized health analytics company founded by leading scientists, physicians, nutritionists, and exercise physiologists from MIT, Harvard, and Tufts University. The InsideTracker platform analyzes and tracks key biochemical and physiological markers as they change over time. InsideTracker uses sophisticated algorithms andlarge scientific databases to determine optimal zones for each user’s markers. InsideTracker’s expert system then provides science-driven lifestyle and nutrition interventions that empower people to optimize their markers. When optimized, these marker levels have been scientifically proven to increase vitality, improve performance and extend life. Its vision is to extend the quality and duration of human life by empowering individuals with the information they need to manage and optimize their own health. We believe that by providing a dynamic, personalized analytic platform at the intersection of biology, science and technology, then distilling the results into simple, natural and sustainable paths for people to follow, we can increase vitality, improve performance and extend the life of every person who is committed to achieving their full potential. | $15M / Series B / Sep 06, 2022 | |
Nowadays
|
Nowadays is building the cheapest and most-scalable manufacturing platform for whole cuts of plant-based meat. | $7M / Seed / Apr 18, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Cornucopian Capital invest in?
Cornucopian Capital invests primarily in Health Care, Biotechnology and Fitness startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cornucopian Capital?
Public channels for Cornucopian Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cornucopian Capital?
The team at Cornucopian Capital includes Aryeh Ganz (Founder & Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
